2/27
09:21 am
rytm
Rhythm Pharmaceuticals (RYTM) had its price target raised by Citizens Jmp from $167.00 to $176.00. They now have a "market outperform" rating on the stock.
Medium
Report
Rhythm Pharmaceuticals (RYTM) had its price target raised by Citizens Jmp from $167.00 to $176.00. They now have a "market outperform" rating on the stock.
2/27
08:02 am
rytm
Rhythm Pharmaceuticals (RYTM) had its price target lowered by Needham & Company LLC from $148.00 to $139.00. They now have a "buy" rating on the stock.
Medium
Report
Rhythm Pharmaceuticals (RYTM) had its price target lowered by Needham & Company LLC from $148.00 to $139.00. They now have a "buy" rating on the stock.
2/27
08:02 am
rytm
Rhythm Pharmaceuticals (RYTM) had its price target raised by Guggenheim from $140.00 to $143.00. They now have a "buy" rating on the stock.
Medium
Report
Rhythm Pharmaceuticals (RYTM) had its price target raised by Guggenheim from $140.00 to $143.00. They now have a "buy" rating on the stock.
2/26
03:10 pm
rytm
Rhythm Pharmaceuticals (RYTM) was given a new $131.00 price target by Stifel Nicolaus.
Low
Report
Rhythm Pharmaceuticals (RYTM) was given a new $131.00 price target by Stifel Nicolaus.
2/26
07:32 am
rytm
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update [Yahoo! Finance]
Medium
Report
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update [Yahoo! Finance]
2/26
07:00 am
rytm
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
Medium
Report
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
2/20
03:21 pm
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) was upgraded by analysts at Royal Bank Of Canada to a "moderate buy" rating.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) was upgraded by analysts at Royal Bank Of Canada to a "moderate buy" rating.
2/19
07:05 pm
rytm
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Should You Buy? [Yahoo! Finance]
Medium
Report
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: Should You Buy? [Yahoo! Finance]
2/19
07:26 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
2/18
08:03 pm
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) was given a new $145.00 price target on by analysts at Royal Bank Of Canada.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) was given a new $145.00 price target on by analysts at Royal Bank Of Canada.
2/18
05:09 pm
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) is now covered by analysts at Royal Bank Of Canada. They set an "outperform" rating on the stock.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) is now covered by analysts at Royal Bank Of Canada. They set an "outperform" rating on the stock.
2/17
08:21 am
rytm
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 [Yahoo! Finance]
Medium
Report
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 [Yahoo! Finance]
2/17
08:00 am
rytm
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
Medium
Report
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
2/5
08:00 am
rytm
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
Medium
Report
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
1/21
06:21 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/20
07:17 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/20
07:17 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "overweight" rating reaffirmed by analysts at Wells Fargo & Company.
1/9
07:03 pm
rytm
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones [Yahoo! Finance]
Low
Report
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones [Yahoo! Finance]
1/9
10:58 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Needham & Company LLC from $145.00 to $148.00. They now have a "buy" rating on the stock.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Needham & Company LLC from $145.00 to $148.00. They now have a "buy" rating on the stock.
1/9
08:00 am
rytm
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
Low
Report
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
1/6
02:26 pm
rytm
Invesco Health Care Fund Q3 2025 Commentary [Seeking Alpha]
Low
Report
Invesco Health Care Fund Q3 2025 Commentary [Seeking Alpha]
12/22
07:18 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/17
08:44 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at UBS Group AG.
12/17
07:06 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/12
11:33 am
rytm
Rhythm Pharmaceuticals Phase 2 Setmelanotide Data Show 'Encouraging' Early Activity, Morgan Stanley Says [Yahoo! Finance]
Low
Report
Rhythm Pharmaceuticals Phase 2 Setmelanotide Data Show 'Encouraging' Early Activity, Morgan Stanley Says [Yahoo! Finance]